Sunday, June 1, 2025
21.5 C
Bengaluru

Specially Designed Case Study based Modules for Pharma Marketing Professionals

DEPA 2.0 Workshop – Open to participants from all companies – Starting February 5th, 2022.

We can also conduct a customized workshop to address your company’s specific needs on dates and timelines convenient to you.

The 4- Module Workshop series will be moderated by Anup Soans with international and Indian faculty – Dr. Peter Velev, a medical doctor and pharma industry veteran, and Salil Kallianpur, pharma marketing veteran and digital brand coach.

Objective: More than digitalizing your product promotions, the case calls for building and engaging your brand community through digital solutions that create memorable customer experiences.

With the new normal emerging, the traditional Pharma commercial model needs to be relooked by exploring alternative channels of engagement, which offer opportunities to create value for customers.

Company-specific digital adoption workshops to experience how a brand can be promoted using the omnichannel approach with field force involvement.

Interactive Webinars extended with Virtual Event – 4 Modules – 2.0 hours each over 4 weeks.

Register Now – https://medicinman.net/depa20-request-payment-link/register-for-depa-2-0/

https://medicinman.net/depa20-request-payment-link/register-for-depa-2-0/

Hot this week

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?

Tata 1mg App Business Model: How does it work...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

Topics

Semaglutide – More Than Just a Patent Battle

The Delhi High Court has restrained Dr. Reddy’s and...

Novo Nordisk — Septerna’s $2.2 Billion Deal

A New Era for Obesity Pills Novo Nordisk has announced...

GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug

In a bold move to strengthen its hepatology pipeline,...

Indian Pharma Market Performance – April 2025

The Indian Pharmaceutical Market (IPM) maintained moderate growth in...

The Future in Your Palm+Chemistry – Palmistry

The future in your palm - a non-contact wearable...

Nimesulide – Nice or Not Nise?

Nimesulide Regulatory Status Worldwide Nimesulide is a non-steroidal anti-inflammatory drug...

MedicinMan Pharma Monitor March 2025

Indian Pharma Top Brands, Therapy & Regional Insights 🏆...
spot_img

Related Articles

spot_imgspot_img